We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb Company (BMY - Free Report) announced an exclusive clinical collaboration agreement with PsiOxus Therapeutics under which the safety, tolerability and preliminary efficacy of PsiOxus’ enadenotucirev will be evaluated in combination with Bristol-Myers’ immuno-oncology drug Opdivo for the treatment of a range of tumor types in late-stage cancer patients.
The clinical collaboration will include phase I studies to assess whether this combination can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses.
We note that Opdivo is a PD-1 immune checkpoint inhibitor while enadenotucirev is a systemically administered oncolytic adenovirus therapeutic.
The deal will see Bristol-Myers shelling out a one-time upfront payment of $10 million to PsiOxus. While both parties will share development costs, PsiOxus will be responsible for conducting a phase I study with patient enrollment expected to commence in the third quarter of 2016. In addition, the companies will work exclusively with each other on anti-PD-1/PD-L1 antagonist antibody and enadenotucirev combination regimens. Moreover, Bristol-Myers will be eligible to get a time-limited right of exclusive negotiation for the commercial rights to enadenotucirev.
We are positive on this deal. Bristol-Myers is collaborating with several other companies for the evaluation of Opdivo in combination with other regimens. The drug recorded worldwide revenues of $942 million in 2015. Label expansion into additional indications would give Opdivo access to an expanded patient population and increase the commercial potential of the drug.
Bristol-Myers is a Zacks Rank #1 (Strong Buy) stock. Some other equally ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Pfizer Inc. (PFE - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bristol-Myers, PsiOxus Strike Immuno-Oncology Collaboration
Bristol-Myers Squibb Company (BMY - Free Report) announced an exclusive clinical collaboration agreement with PsiOxus Therapeutics under which the safety, tolerability and preliminary efficacy of PsiOxus’ enadenotucirev will be evaluated in combination with Bristol-Myers’ immuno-oncology drug Opdivo for the treatment of a range of tumor types in late-stage cancer patients.
The clinical collaboration will include phase I studies to assess whether this combination can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses.
We note that Opdivo is a PD-1 immune checkpoint inhibitor while enadenotucirev is a systemically administered oncolytic adenovirus therapeutic.
The deal will see Bristol-Myers shelling out a one-time upfront payment of $10 million to PsiOxus. While both parties will share development costs, PsiOxus will be responsible for conducting a phase I study with patient enrollment expected to commence in the third quarter of 2016. In addition, the companies will work exclusively with each other on anti-PD-1/PD-L1 antagonist antibody and enadenotucirev combination regimens. Moreover, Bristol-Myers will be eligible to get a time-limited right of exclusive negotiation for the commercial rights to enadenotucirev.
We are positive on this deal. Bristol-Myers is collaborating with several other companies for the evaluation of Opdivo in combination with other regimens. The drug recorded worldwide revenues of $942 million in 2015. Label expansion into additional indications would give Opdivo access to an expanded patient population and increase the commercial potential of the drug.
Bristol-Myers is a Zacks Rank #1 (Strong Buy) stock. Some other equally ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Pfizer Inc. (PFE - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>